Trials / Completed
CompletedNCT00778921
Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients With Hypertension Not Adequately Responding to Amlodipine Alone
A Randomized, Eight Week Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / Amlodipine (150/10 mg and 300/10 mg) in Comparison With Amlodipine 10 mg in Patients With Essential Hypertension Not Adequately Responsive to Amlodipine 10 mg Monotherapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 847 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the safety and efficacy of combination aliskiren/amlodipine in patients with hypertension not adequately controlled with amlodipine alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Amlodipine 10 mg | Amlodipine 10 mg |
| DRUG | Aliskiren 150 | Aliskiren/Amlodipine 150/10 mg |
| DRUG | Amlodipine 300 | Aliskiren/Amlodipine 300/10 mg |
Timeline
- Start date
- 2008-10-01
- Primary completion
- 2009-06-01
- Completion
- 2009-06-01
- First posted
- 2008-10-24
- Last updated
- 2016-10-27
- Results posted
- 2011-03-23
Locations
7 sites across 7 countries: Argentina, Germany, Norway, Poland, Slovakia, Sweden, Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT00778921. Inclusion in this directory is not an endorsement.